Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today announced the availability of the Brand Perception Series: Physician Segmentation, which identifies key physician segments to uncover targeted opportunities for current and emerging drug brands. This series offers a fresh look at a competitive drug market by analyzing physician perception of current and emerging drugs using unique physician profiles that will help biopharmaceutical companies understand and size market opportunities.

"As drug markets become saturated with brand and generic competition, it is increasingly challenging for drug marketers to formulate effective product differentiation and positioning strategies," said Decision Resources Director Nicole Westphal, Ph.D. "With Brand Perception Series: Physician Segmentation, Decision Resources identifies key segments of physicians, characterizes the segments based on demographic and behavioral variables and explores the reasons behind segments' current and emerging product perceptions to help biopharmaceutical teams build product strategies that will resonate with high-opportunity prescribers."

  Four Reports Now Available   Four new reports for 2010 are now available, including:    --  Brand Perceptions Series: Physician Segmentation in Chronic       Obstructive Pulmonary Disease which finds that efficacy in alleviating       symptoms, improving breathing and frequency of exacerbations are key       drivers of brand choice across all physician segments.   --  Brand Perception Series: Physician Segmentation in Major Depressive       Disorder which finds that when prescribing drugs for depressed       patients, safety-minded physicians in independent practices may       sacrifice efficacy and/or cost for safety.   --  Brand Perception Series: Physician Segmentation in Parkinson's Disease       which finds that Teva/Lundbeck's Azilect is neurologists' top overall       agent for the treatment of Parkinson's disease, based primarily on       their favorable perception of the brand's disease       modifying/neuroprotective effect.   --  Brand Perception Series: Physician Segmentation in Rheumatoid       Arthritis which finds that physicians perceive that different brands       within the TNF-alpha inhibitor drug class have distinct strengths and       weaknesses, despite clinical data suggesting that agents in this class       have similar efficacy to each other.  

Each report includes an analysis of physician segments based on their drivers of brand choice, along with a segment-by-segment look at both perception of currently marketed therapies and drivers of emerging therapy use.

In 2010, additional reports from Brand Perception Series: Physician Segmentation will include:

  --  Asthma   --  Insulins   --  Multiple Sclerosis   --  Noninsulin Antidiabetics   --  Psoriasis    About Decision Resources 

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                        Decision Resources, Inc.   Lisa Osgood                               Christopher Comfort   781-296-2606                              781-296-2597   losgood@hl-isy.com                        ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Lisa Osgood of Decision Resources, +1-781-296-2606,
losgood@hl-isy.com, or Christopher Comfort of Decision Resources, Inc.,
+1-781-296-2597, ccomfort@dresources.com

The Majority of Surveyed Clinicians Who Have Prescribed Nucynta for Inflammatory and Nociceptive Pain Perceive the Drug to Have Efficacy That is Comparable to Oxycodone

View Now